Münster

• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• Intravenous Fish Oil based Lipid Emulsion to enhance recovery in High-Risk Cardiac Surgery Patients: a phase II multicenter trial Recruiting
  2023-503490-38-00 4 2023-11-15 critical illness, intensive care unit (ICU), surgery
• Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: … Recruiting
  2023-503558-10-00 5 2023-10-13 oligometastatic pancreatic cancer
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24) Recruiting
  2024-511264-89-00 4 2022-04-11 Glioblastoma
• EPO-TRAUMA Recruiting
  2023-506081-31-00 5 2022-03-29 Traumatic Injury
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica … Recruiting
  2022-501454-11-00 5 2020-02-05 standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended recruitment
  2024-515089-15-00 5 2025-02-28 active non-infectious uveitis (intermediate uveitis, posterior uveitis
• Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended recruitment
  2022-502878-16-00 5 2025-01-23 Acute ischemic strokes with incomplete reperfusion
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema … Ended recruitment
  2024-510944-30-00 10 2024-11-22 Diabetic Macular Edema
• ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub … Ended recruitment
  2024-511482-11-00 5 2024-11-20 Dry Age-Related Macular Degeneration (Dry AMD)
• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended recruitment
  2023-504040-34-01 5 2024-11-12 Crohn’s Disease
• REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m … Ended recruitment
  2023-509600-15-00 5 2024-10-18 Type 2 Diabetes
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended recruitment
  2022-502634-52-00 5 2023-05-16 prostate cancer

Showing 25–48 of 74 trials